RECRUITING

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

Conditions

Malignant Peritoneal Mesothelioma Peritoneal Mesothelioma Mesothelioma Mesothelioma, Malignant Malignant Mesothelioma ICARuS II Memorial Sloan Kettering Cancer Center 23-145

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.

Official Title

ICARuS II (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multicenter, Randomized Phase II Trial of Normothermic Intraperitoneal Chemotherapy and Intravenous Chemotherapy After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma

Quick Facts

Study Start:2023-09-21

Study Completion:2028-09-21

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06057935

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Patient age 18 years or older, both sexes. * Clinical diagnosis of MPM at enrolling institution. * Prior to randomization, intraoperative pathologic confirmation of epithelioid MPM at enrolling institution. * Complete or near-complete CRS achieved. * Patient must be planning to undergo complete cytoreduction of all peritoneal disease. * ECOG performance status ≤ 1. * Hematology: ANC ≥ 1,500/µl. * Platelets \> 75,000/µl. * Adequate renal function: creatinine \< 1.5× the upper limit of normal (ULN) or calculated creatinine clearance of ≥50 ml/min. * Adequate hepatic function: bilirubin \< 1.5 mg/dl (except in patients with Gilbert's syndrome, who must have total bilirubin \< 3.0 mg/dL). * Women of childbearing potential with a negative pregnancy test result (urine or blood) who agree to use an effective contraceptive method. Reliable contraception should be used from trial screening and must be continued throughout the study. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. * A man participating in this study must agree to utilize a reliable barrier form of contraception for the duration of the study * Signed and dated written informed consent to participate in this clinical trial must be obtained prior to any study procedure.	* Subjects who have previously undergone intraperitoneal chemotherapy or systemic chemotherapy for peritoneal mesothelioma. * Subjects who have previously received platinum-containing chemotherapy regimens. * Subjects with preoperative or intraoperative biopsy consistent with sarcomatoid mesothelioma, well-differentiated papillary mesothelioma, or benign multicystic mesothelioma. * Other prior malignancies, except for cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix, adequately treated malignancies for which there has been no evidence of activity for more than three years, or indolent tumors for which observation over two years is a reasonable option. * High suspicion for extra-abdominal metastases. * Women who are pregnant or lactating. * Active coronary artery disease (defined as unstable angina or a positive cardiac stress test). Subjects with a history of coronary artery disease may be included if they have had a normal stress test within 60 days of enrollment or are determined by a cardiologist to be of acceptable perioperative risk. * Uncontrolled hypertension defined as \>140/90 and not cleared for surgery at the time of consent. * New York Heart Association (NYHA) Class II or higher congestive heart failure; restrictive or obstructive pulmonary disease that would limit study compliance or place the patient at unacceptable risk for participation in the study. * History of cerebrovascular disease that would limit study compliance or place the patient at unacceptable risk for participation in the study. * Subjects with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or place them at an unacceptable risk for participation in the study. * Patients with known cisplatin, carboplatin, pemetrexed or mitomycin allergy. * Evidence of extensive intraperitoneal adhesions at the time of surgery which prohibits intraperitoneal therapy, as determined by the operating surgeon. * Any condition that would preclude the ability to deliver appropriate IP therapy. * Use of an oral medication, lacking a suitable non-oral substitute, that if held for up to ten days, would be felt an unacceptable risk by the investigator. * Life expectancy \< 12 weeks.

Inclusion Criteria

Exclusion Criteria

* Patient age 18 years or older, both sexes.
* Clinical diagnosis of MPM at enrolling institution.
* Prior to randomization, intraoperative pathologic confirmation of epithelioid MPM at enrolling institution.
* Complete or near-complete CRS achieved.
* Patient must be planning to undergo complete cytoreduction of all peritoneal disease.
* ECOG performance status ≤ 1.
* Hematology: ANC ≥ 1,500/µl.
* Platelets \> 75,000/µl.
* Adequate renal function: creatinine \< 1.5× the upper limit of normal (ULN) or calculated creatinine clearance of ≥50 ml/min.
* Adequate hepatic function: bilirubin \< 1.5 mg/dl (except in patients with Gilbert's syndrome, who must have total bilirubin \< 3.0 mg/dL).
* Women of childbearing potential with a negative pregnancy test result (urine or blood) who agree to use an effective contraceptive method. Reliable contraception should be used from trial screening and must be continued throughout the study. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant.
* A man participating in this study must agree to utilize a reliable barrier form of contraception for the duration of the study
* Signed and dated written informed consent to participate in this clinical trial must be obtained prior to any study procedure.

* Subjects who have previously undergone intraperitoneal chemotherapy or systemic chemotherapy for peritoneal mesothelioma.
* Subjects who have previously received platinum-containing chemotherapy regimens.
* Subjects with preoperative or intraoperative biopsy consistent with sarcomatoid mesothelioma, well-differentiated papillary mesothelioma, or benign multicystic mesothelioma.
* Other prior malignancies, except for cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix, adequately treated malignancies for which there has been no evidence of activity for more than three years, or indolent tumors for which observation over two years is a reasonable option.
* High suspicion for extra-abdominal metastases.
* Women who are pregnant or lactating.
* Active coronary artery disease (defined as unstable angina or a positive cardiac stress test). Subjects with a history of coronary artery disease may be included if they have had a normal stress test within 60 days of enrollment or are determined by a cardiologist to be of acceptable perioperative risk.
* Uncontrolled hypertension defined as \>140/90 and not cleared for surgery at the time of consent.
* New York Heart Association (NYHA) Class II or higher congestive heart failure; restrictive or obstructive pulmonary disease that would limit study compliance or place the patient at unacceptable risk for participation in the study.
* History of cerebrovascular disease that would limit study compliance or place the patient at unacceptable risk for participation in the study.
* Subjects with other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or place them at an unacceptable risk for participation in the study.
* Patients with known cisplatin, carboplatin, pemetrexed or mitomycin allergy.
* Evidence of extensive intraperitoneal adhesions at the time of surgery which prohibits intraperitoneal therapy, as determined by the operating surgeon.
* Any condition that would preclude the ability to deliver appropriate IP therapy.
* Use of an oral medication, lacking a suitable non-oral substitute, that if held for up to ten days, would be felt an unacceptable risk by the investigator.
* Life expectancy \< 12 weeks.

Contacts and Locations

Study Contact

Garrett Nash, MD

CONTACT

212-639-8668

nashg@mskcc.org

Michael Offin, MD

CONTACT

646-608-3763

offinm@mskcc.org

Principal Investigator

Garrett Nash, MD

PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer

Study Locations (Sites)

University of Chicago (Data Collection Only)

Chicago, Illinois, 60637

United States

University of Michigan (Data Collection Only)

Ann Arbor, Michigan, 48109

United States

Washington University (Data Collection Only)

Saint Louis, Missouri, 63110

United States

University of Nebraska (Data collection only)

Omaha, Nebraska, 68198-7680

United States

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920

United States

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748

United States

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645

United States

Rutgers University (Data Collection Only)

New Brunswick, New Jersey, 08903

United States

Memorial Sloan Kettering Commack (Limited Protocol Activities)

Commack, New York, 11725

United States

Memorial Sloan Kettering Westchester (Limited Protocol Activites)

Harrison, New York, 10604

United States

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065

United States

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553

United States

Allegheny Health Network (Data Collection Only)

Pittsburgh, Pennsylvania, 15212

United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

Garrett Nash, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-21

Study Completion Date2028-09-21

Study Record Updates

Study Start Date2023-09-21

Study Completion Date2028-09-21

Terms related to this study

Keywords Provided by Researchers

Malignant Peritoneal Mesothelioma
Peritoneal Mesothelioma
Mesothelioma
Mesothelioma, Malignant
Malignant Mesothelioma
ICARuS II
Memorial Sloan Kettering Cancer Center
23-145

Additional Relevant MeSH Terms

Malignant Peritoneal Mesothelioma
Peritoneal Mesothelioma
Mesothelioma
Mesothelioma, Malignant
Malignant Mesothelioma